Notícias e Atividades da Immunocore
Executivos
Veja o organograma con seus 29 executivos principais
Biografias mais buscadas da Immunocore
- Bahija Jallal, Chief Executive Officer and Director
- Siddharth Kaul, Non-Executive Director
- Peter Ratcliffe, Non-Executive Director
Recentes movimentos de executivos em Immunocore
- Mohammed Dar antes Head of Clinical Development and Chief Medical Officer, foi promovido a Executive Vice President, Clinical Development and Chief Medical Officer (Notícia publicada em 30 de janeiro de 2026).
- David Berman, Head of Research & Development, deixará a Companhia em 27 de fev. de 2026 (Notícia publicada em 30 de janeiro de 2026).
- Tina St. Leger, Chief Human Resources Officer, deixou a Companhia (Notícia publicada em 1 de dezembro de 2025).
Criar um alerta
para seguir os movimentos de executivos da Immunocore.
Biotecnologia
Immunocore possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).
Popular M&A news in Biotecnologia
- Eli Lilly has announced the acquisition of AtaiBeckley (publicado em 17 de julho de 2026).
- GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
- Clearside Biomedical has gone out of its bankruptcy protection (publicado em 15 de julho de 2026).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Immunocore
- Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine :: Immunocore PLC
- Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial :: Immunocore PLC
- Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 :: Immunocore PLC
- Immunocore to present at upcoming investor conferences :: Immunocore PLC
- Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
- Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
- Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update :: Immunocore PLC
- Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting :: Immunocore
- Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B :: Immunocore
- Immunocore Reports First Quarter 2021 Financial Results :: Immunocore
- View more press releases Close
Redes sociais sobre Immunocore
- Immunocore na Wikipedia, Google News e Yahoo Finance
- Immunocore na LinkedIn, X (Twitter) e YouTube
